Two development programs, one active molecule
Compass Pathways and Usona Institute are both pursuing standardized psilocybin medicines, but their programs are not interchangeable. COMP360 is Compass’s proprietary synthetic psilocybin formulation, developed primarily for treatment-resistant depression. Usona’s psilocybin research program, often discussed under the PSIL201 name, is directed at major depressive disorder. Both involve medically supervised administration rather than take-home mushroom products.
The biggest difference is the intended patient population
Treatment-resistant depression generally requires an inadequate response to at least two appropriate antidepressant courses. Major depressive disorder is a broader diagnosis and does not automatically require a history of failed medication trials. Consequently, the two applications could result in different eligibility criteria even though both involve psilocybin. The final FDA-approved indications, if any, will be determined by the evidence and labeling, not by broad marketing descriptions.
How their research programs differ
Compass completed a new drug application for COMP360 on November 9, 2026, citing two positive Phase 3 trials and a Phase 2b study. Its program includes research into symptom improvement and the possible durability of benefit following intermittent dosing. Usona completed a Phase 2 study and enrolled participants in its Phase 3 uAspire trial, which examined a single 25 mg dose against lower-dose and placebo comparisons with follow-up over time. The designs, populations and outcomes must be evaluated individually; success in one program does not validate the other.
Does one require more therapy?
Both programs incorporate psychedelic psychological or psychosocial support, but the specifics of preparation, dosing-session supervision and post-session care are not identical. Neither should be described as a conventional medication that a patient simply takes at home. The FDA may require monitoring, trained staff, facility safeguards or additional safety measures. Until labeling is finalized, comparisons about the number of required therapists or visits remain provisional.
What about patents and pricing?
Compass has pursued a proprietary formulation and a commercial launch strategy. Usona operates as a nonprofit and has publicly emphasized research access and scientific development. These differences may influence licensing, commercial partnerships and eventual pricing, but they do not allow a reliable prediction that one treatment will cost less. Drug price is only one part of total treatment expense; a full-day supervised appointment, preparation and follow-up can also create substantial costs.
Which could become available first?
Compass’s application completion is publicly documented. Usona’s application was reported by specialist outlets in early November, but public confirmation and the FDA’s acceptance or review schedule should be monitored separately. Reports that the FDA’s priority voucher program has been curtailed add uncertainty to accelerated timelines. Even an approval decision would not necessarily mean immediate availability in California, because controlled-substance scheduling and clinic readiness may take additional time.
What patients should take away
The practical distinction is not which brand sounds more familiar. It is whether the eventual approved indication matches the patient’s diagnosis and treatment history, whether the risks are acceptable and whether a qualified clinic can provide the treatment. For now, both remain investigational, and patients should avoid claims that either product is already an FDA-approved routine treatment.
Learn More About Psychedelic Therapy in California
Whether you’re exploring treatment options or looking for information specific to your region, continue your research with these guides.
Treatment Guides
- MDMA Therapy in California
- Psilocybin Therapy in California
- Ketamine Therapy
- Psychedelic Integration Therapy
- Psychedelic Clinical Trials California
Regional Guides
- Bay Area Psychedelic Therapy Guide
- Los Angeles Psychedelic Therapy Guide
- Orange County Psychedelic Therapy Guide
- San Diego Psychedelic Therapy Guide
- Sacramento Psychedelic Therapy Guide
- San Jose Psychedelic Therapy Guide
- Silicon Valley Psychedelic Therapy Guide
- Inland Empire Psychedelic Therapy Guide
- Central Coast Psychedelic Therapy Guide

